More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.

U.S. President Donald Trump will meet on Thursday with chief executives from major drugmakers, a White House official ...

Healthcare costs and spending have been rising in the US. The Centers for Medicare & Medicaid Services reported that ...

The biosimilars reach the US market as the US insulin space has seen seismic changes in the last few years, with a clamour of ...

While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...

U.S. President Donald Trump is set to meet with top pharmaceutical executives on Thursday, a White House official confirmed. The discussions will focus on Medicare drug price negotiations, pharmacy ...

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

Eli Lilly (LLY) stock and Novo Nordisk (NVO) stock face investor scrutiny as RFK Jr. takes the leadership of HHS. Read more ...

Last year was a pivotal year for the pharmaceutical industry. Under the IRA’s Medicare Drug Price Negotiation Program (the ...

The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...

Trump previously met with Ubl and chief executives of U.S. drugmakers Pfizer and Eli Lilly at his Mar-a-Lago estate in Florida in December.

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...